Showing results (731-740 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|April 22, 2014
The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein--a well-known, yet poorly understood drug transporterMaen Zeino, Mohamed E M Saeed, Onat Kadioglu, et al.
Investigational New Drugs|May 2, 2008
The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinibRoos L Oostendorp, Tessa Buckle, Jos H Beijnen, et al.
Investigational New Drugs|April 22, 2008
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancerJohan Vansteenkiste, Eric Van Cutsem, Herlinde Dumez, et al.
Investigational New Drugs|February 12, 2008
Evaluation of the therapeutic efficacy of tripeptide tyroserleutide (YSL) for human hepatocarcinoma by in vivo hollow fiber assayXiao-lei Li, Jun-yan Liu, Rong Lu, et al.
Investigational New Drugs|February 12, 2008
Inhibitory effects of quercetin derivatives on phosphodiesterase isozymes and high-affinity [(3) H]-rolipram binding in guinea pig tissuesAgnes L-F Chan, Hui-Lin Huang, Hui-Chi Chien, et al.
Investigational New Drugs|February 1, 1991
A phase II study of menogaril in low-grade non-Hodgkin's lymphoma. An NCI Canada Clinical Trials Group studyJ Skillings, C Cripps, E Eisenhauer, et al.
Investigational New Drugs|November 5, 2016
Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studiesAlexandra Tyulyandina, Daniel Harrison, Wei Yin, et al.
Investigational New Drugs|May 23, 2008
Effect of morin on tissue lipid peroxidation and antioxidant status in 1, 2-dimethylhydrazine induced experimental colon carcinogenesisVennila Sreedharan, Karthik Kumar Venkatachalam, Nalini Namasivayam
Investigational New Drugs|February 26, 2014
A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancerAlan L Ho, Brynna L Lipson, Eric J Sherman, et al.
Investigational New Drugs|February 26, 2014
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trialA Necchi, P Giannatempo, L Mariani, et al.
Pageof 372